BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,286 from $950 and keeps a Buy rating on the shares with the company nearing the launch of a closely watched new oral GLP1 drug, orforglipron, on an accelerated basis after being awarded one of the FDA’s first Commissioner’s National Priority Vouchers. Lilly continues to be “solidly in first place” in the large obesity and diabetes market with its current GLP1 franchise, while pushing through a broad phase 3 development program with its high-potency product, retatrutide, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- NVO,LLY: Shares Drop as World Health Organization Calls for Cheaper Versions of Weight-Loss Drugs
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
- Eli Lilly (LLY) Lowers Price of Weight-Loss Drug on Direct-to-Consumer Site
- Trump Trade: U.S. confirms agreement with U.K. on pharmaceutical pricing